Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients

Xufré, Cristina; González, Tanía; Leal, Lorna; Trubey, Charles M; Lifson, Jeffrey D; Gatell, José María; Alcamí, José; Climent, Núria; García, Felipe; Sánchez-Palomino, Sonsoles

Publication:
Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients

dc.contributor.author	Xufré, Cristina
dc.contributor.author	González, Tanía
dc.contributor.author	Leal, Lorna
dc.contributor.author	Trubey, Charles M
dc.contributor.author	Lifson, Jeffrey D
dc.contributor.author	Gatell, José María
dc.contributor.author	Alcamí, José
dc.contributor.author	Climent, Núria
dc.contributor.author	García, Felipe
dc.contributor.author	Sánchez-Palomino, Sonsoles
dc.contributor.funder	Ministerio de Economía (España)
dc.contributor.funder	Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funder	Instituto de Salud Carlos III
dc.contributor.funder	Red de Investigación Cooperativa en Investigación en Sida (España)	es_ES
dc.contributor.funder	Government of Catalonia (España)
dc.contributor.funder	Fundación La Caixa
dc.contributor.funder	NIH - National Cancer Institute (NCI) (Estados Unidos)
dc.date.accessioned	2022-12-20T07:10:28Z
dc.date.available	2022-12-20T07:10:28Z
dc.date.issued	2022-04
dc.description.abstract	We described a novel HIV autologous isolation method based in coculturing macrophages and CD4+T-cell-enriched fractions from peripheral blood collected from antiretroviral-treated (ART) HIV patients. This method allows the isolation of high viral titers of autologous viruses, over 1010HIV RNA copies/ml, and reduces the time required to produce necessary amounts for virus for use as antigens presented by monocyte-derived myeloid cells in HIV therapeutic vaccine approaches. By applying these high titer and autologous virus produced in the patient-derived cells, we intended to elicit a boost of the immunological system response in HIV therapeutic vaccines in clinical trials.	es_ES
dc.description.peerreviewed	Sí	es_ES
dc.description.sponsorship	This study was partially supported by grants from the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, SAF-2017-88089-R, RTI2018-096309-B-I00); the Fondo Europeo para el Desarrollo Regional (FEDER); the SPANISH AIDS Research Network RD16/0025/0002 and RD16/0025/0014-ISCIII-FEDER (RIS); the Fondo de Investigación Sanitaria (FIS) PI12/01247 and PI20/00676; and HIVACAT program and the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653. The project leading to these results has received funding from “la Caixa” Foundation under agreement. This study was also supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract Nos. HHSN261200800001E and 75N91019D00024.	es_ES
dc.format.page	869431	es_ES
dc.format.volume	2	es_ES
dc.identifier.citation	Front Virol. 2022 Apr;2:869431.	es_ES
dc.identifier.doi	10.3389/fviro.2022.869431	es_ES
dc.identifier.e-issn	2673-818X	es_ES
dc.identifier.journal	Frontiers in Virology	es_ES
dc.identifier.pubmedID	35967461	es_ES
dc.identifier.uri	http://hdl.handle.net/20.500.12105/15287
dc.language.iso	eng	es_ES
dc.publisher	Frontiers Media
dc.relation.projectFECYT	info:eu-repo/grantAgreement/MINECO//SAF2015-66193-R/ES/UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA INMUNOGENICIDAD Y EFICACIA DE VACUNAS TERAPEUTICAS FRENTE A VIH/	es_ES
dc.relation.projectFECYT	info:eu-repo/grantAgreement/ES/SAF-2017-88089-R	es_ES
dc.relation.projectFECYT	info:eu-repo/grantAgreement/ES/RTI2018-096309-B-I00	es_ES
dc.relation.projectFECYT	info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0002/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/	es_ES
dc.relation.projectFIS	info:eu-repo/grantAgreement/ES/RD16/0025/0014-ISCIII-FEDER	es_ES
dc.relation.projectFIS	info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2012) (2012)/PI12/01247	es_ES
dc.relation.projectFIS	info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20 - Proyectos de investigacion en salud (AES 2020). Modalidad proyectos de investigación en salud. (2020)/PI20/00676	es_ES
dc.relation.publisherversion	https://doi.org/10.3389/fviro.2022.869431	es_ES
dc.repisalud.centro	ISCIII::Centro Nacional de Microbiología (CNM)	es_ES
dc.repisalud.institucion	ISCIII	es_ES
dc.rights.accessRights	open access	es_ES
dc.rights.license	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	CD4+ T cells	es_ES
dc.subject	HIV isolation	es_ES
dc.subject	HIV therapeutic vaccine	es_ES
dc.subject	Autologous HIV immunogen	es_ES
dc.subject	Coculture	es_ES
dc.subject	Monocyte-derived macrophages (MDM)	es_ES
dc.title	Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients	es_ES
dc.type	research article	es_ES
dc.type.hasVersion	VoR	es_ES
dspace.entity.type	Publication
relation.isAuthorOfPublication	2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery	2fc55aca-54b0-411c-b170-c2149068a902
relation.isFunderOfPublication	ca7182dc-aaab-45ec-a09d-755563fe05f2
relation.isFunderOfPublication	efa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication	7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication	c6fbffec-abb4-4f0e-81e0-3b254d5dd85d
relation.isFunderOfPublication	f04d23ec-a91d-4242-88b0-cc436888f8a2
relation.isFunderOfPublication	b589134c-ce3e-4f64-a3f5-83d0a7eb706a
relation.isFunderOfPublication.latestForDiscovery	ca7182dc-aaab-45ec-a09d-755563fe05f2
relation.isPublisherOfPublication	9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery	9f9fa5ea-093b-43d8-bf2c-5bd65d08a802